Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

DRAGON PHARMACEUTICAL INC

Form 8-K April 08, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2005

DRAGON PHARMACEUTICAL INC. (Exact name of registrant as specified in its charter)

Florida 0-27937 65-0142474 -----

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Incorporation) Identification No.)

1055 Hastings Street, Suite 1900
Vancouver, British Columbia
V6E 2E9
-----(Address of Principal Executive Offices)
(Zip Code)

(604) 669-8817

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 7 - Regulation FD

Item 7.01 Regulation FD Disclosure

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

Dragon Pharmaceutical Inc. announced its business update after the completion of acquisition of Oriental Wave and selected unaudited 2004 pro-forma combined financial data on the attached press release.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibit No.	Exhibit Description

Press release announcing business update after the completion of acquisition of Oriental Wave and selected unaudited 2004 pro-forma combined financial data

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DRAGON PHARMACEUTICAL INC., a Florida Corporation

Dated: April 5, 2005 /s/ Maggie Deng

Maggie Deng

Chief Operating Officer

EXHIBIT INDEX

Exhibit No. Description

99 Press release dated April 4, 2005 titled "Dragon Pharmaceutical Announces Business Update after the Completion of Acquisition of Oriental Wave and Selected Unaudited 2004 Pro-forma Combined Financial Data"